Status of IDH mutations in chondrosarcoma of the jaws

alwin shared this article with you from Inoreader Status of IDH mutations in chondrosarcoma of the jaws Via International Journal of Oral and Maxillofacial Surgery The aim was to analyse the relationship between mutations of the isocitrate dehydrogenase gene (IDH) and clinical characteristics of chondrosarcoma of the jaw in order to provide new information on its molecular pathology. Tissue samples were collected from 25 patients diagnosed with chondrosarcoma of the jaw. IDH mutations were detected through polymerase chain reaction and direct sequencing. Clinicopathological data were analysed retrospectively. The study included 14 female and 11 male patients; the median patient age was 38 years. (Source: International Journal of Oral and Maxillofacial Surgery) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension

alwin shared this article with you from Inoreader Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension Via ScienceDirect Publication: Journ... Publication date: 19 April 2022 Source: Journal of the American College of Cardiology, Volume 79, Issue 15 Author(s): Yu-Ping Zhou, Yun-Peng Wei, Yin-Jian Yang, Xi-Qi Xu, Tao Wu, Chao Liu, Ke-Yi Mei, Fu-Hua Peng, Hai-Ping Wang, Kai Sun, Jing-Yi Li, Hui-Fang Wang, Meng-Tao Li, Duo-Lao Wang, Qi Miao, Xin Jiang, Zhi-Cheng Jing View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma

alwin shared this article with you from Inoreader Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma Via Oncology CONCLUSION: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with synovial sarcoma was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for synovial sarcomas.PMID:35405680 | DOI:10.1159/000524500 (Source: Oncology) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Retrospective analysis of adjuvant radiotherapy in oral cavity or oropharyngeal cancer: Feasibility of omitting lower-neck irradiation

als.fakia shared this article with you from Inoreader Retrospective analysis of adjuvant radiotherapy in oral cavity or oropharyngeal cancer: Feasibility of omitting lower-neck irradiation Via Head and neck cancers by Sheng-Yow Ho, Wan-Chen Kao, Sheng-Yen Hsiao, Sheng-Fu Chiu, Sung-Wei Lee, Jia-Chun Chen, Li-Tsun Shieh Objectives Adjuvant radiotherapy is the standard of care in locally advanced head and neck cancers. The radiation field is correlated with the surgical field in the adjuvant radiotherapy setting; therefore, tailoring the irradiation field is reasonable. Materials and methods We retrospectively analyzed patients with oral cavity and oropharyngeal cancers included in the cancer registry between 2015 and 2019 in the study hospital. Patients who underwent whole-neck irradiation (WNI) were compared with those who underwent lower-neck–sparing (LNS) irradiation. Results A total of 167 patients with oral cavity and oropharyngeal cancers were included in the study. Cancer recurrence was recorded in 33% of the patients. The rate of recurrence of oral cavity and oropharyngeal cancer at neck level IV was 8%. The 2-year incidence of level IV recurrence was lower in the WNI group than in the LNS group (2% vs. 10%; p = 0.04). The 2-year disease-free survival rates were 75% and 63% in the WNI and LNS groups, respectively (p = 0.08). Conclusion The rate of level IV recurrence was higher in the LNS group than in the WNI group. Trends of improvement in disease-free survival with lower-neck irradiation suggested that it is premature to consider LNS irradiation as daily practice in patients with oral cavity and oropharyngeal cancer. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.